Abstract
In the past few years, there has been a rapid development in China's generic drug market, while the new drug innovation performance is not outstanding. As an effective means to achieve multiple policies for the government, drug price not only maintains the new health reform target of drug accessibility and lower drug costs, but also plays a crucial role in drug innovation incentives. Through the analysis of current situation of Chinese medicine manufacturing drug innovation and existing problems, the authors discussed the role of drug price incentive compensation mechanism in innovation, and proposed the following price incentive strategy, using the pharmacoeconomics evaluation system, into the compensation directory, setting up the mechanism of drug price negotiations and by means of controlling medical costs.
Highlights
The Main Part of Drug DevelopmentWith the implementation of the strategy "building an innovative country" in China, the concept of "enterprise is the main body of technology innovation" has reached consensus
In the past few years, there has been a rapid development in China's generic drug market, while the new drug innovation performance is not outstanding
Through the analysis of current situation of Chinese medicine manufacturing drug innovation and existing problems, the authors discussed the role of drug price incentive compensation mechanism in innovation, and proposed the following price incentive strategy, using the pharmacoeconomics evaluation system, into the compensation directory, setting up the mechanism of drug price negotiations and by means of controlling medical costs
Summary
With the implementation of the strategy "building an innovative country" in China, the concept of "enterprise is the main body of technology innovation" has reached consensus. From the developing trend of recent five years, the R&D investment of biological medicine high-tech enterprises is growing rapidly, the average annual growth rate is 45%, which is higher than the average level of China's high technology industry 33%. 1 class new drug of biological products refers to the never sold therapeutic biologics or vaccine in domestic and foreign market, 2 class new drug refers to the monoclonal antibody or DNA vaccines, 3 class new drug refers to gene therapy, cell therapy and its products, or the new adjuvants changed from the selling vaccine, the new carrier changed from coupling vaccine It is short of a whole for the Chinese government to control the compensation standard, evaluation, pricing and regulatory scrutiny of innovative drugs. It is mainly manifested in the following aspects, the government didn't do scientific and reasonable evaluation of drug innovation for pricing, and innovative drugs is difficult to be listed by the medical insurance directory
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
